Form 4: Rosemary Crane Reports TEVA Share Transactions
Statement of Changes in Beneficial Ownership
Rosemary A. Crane, a Director at TEVA Pharmaceutical Industries Ltd., reported transactions involving ordinary shares and restricted share units.
Summary
- Rosemary A. Crane, a Director at TEVA Pharmaceutical Industries Ltd., filed a Form 4 detailing changes in her beneficial ownership of company securities.
- On June 5, 2026, 14,492 ordinary shares were acquired.
- Also on June 5, 2026, 14,492 restricted share units vested. These units were granted on June 5, 2025.
- Following these transactions, Crane beneficially owns 127,739 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions related to compensation and ownership rather than significant strategic or financial performance indicators.
Positives
- Director Rosemary A. Crane acquired 14,492 ordinary shares, indicating continued investment or compensation.
- Vesting of 14,492 restricted share units on June 5, 2026, suggests achievement of performance or service conditions.
- The reporting person directly holds a significant number of shares (127,739), demonstrating substantial beneficial ownership.
Future Outlook
No specific forward-looking statements or guidance were provided in this Form 4 filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical industry, providing transparency on executive and director holdings and movements.
Stakeholder Impact
- Shareholders: Increased transparency into director's holdings and potential alignment of interests.
- Employees: Vesting of restricted share units may be tied to company performance or service, impacting employee incentives.
- Management: Standard reporting requirement, ensuring compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date restricted share units were granted. |
| 06/05/2026 | Date of earliest transaction reported; date of acquisition of ordinary shares and vesting of restricted share units. |
| 06/08/2026 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
Keywords
TEVA Pharmaceutical Industries, Form 4, Securities Ownership, Director Transactions, Restricted Share Units, Ordinary Shares, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.